RGCC and myeloid sarcoma: The potential biomarkers which can be used to predict the prognosis of relapsed or progressive forms of MS, as well as the responsiveness to treatment in patients with MS are SIRT1 (a NAD-dependent deacetylase sirtuin-1) mRNA, Response gene to complement-32 (RGC-32), Fasl, IL-21, Tau proteins (proteins that stabilize microtubules), miR-191-5p, miR-128-3p and serum netrin-1 (an axon guidance protein) [17,21,29,30,31,32].